Form 8-K CYTOKINETICS INC For: Sep 15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St set for lower open as bond yields climb; Walmart falls
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Cytokinetics meets with FDA on aficamten drug application
September 16, 2025 4:12 PM EDTCytokinetics (NASDAQ: CYTK) participated in a late cycle meeting with the Food and Drug Administration on September 15, 2025, regarding its new drug application for aficamten in obstructive hypertrophic cardiomyopathy.
The company discussed its proposed risk evaluation and mitigation strategy program and anticipated post-marketing... More
